Barclays capital-at-risk pharma note pays 9.75% in the US

Coupons and capital risk

pharmacy-pills

Barclays in the US has issued a 12-month structured product tied to the performance of the common stock of Valeant Pharmaceuticals International. The note will pay a fixed monthly coupon even if the price of the underlying falls below the barrier level during the monitoring period. Capital is at risk if the price of the underlying stock falls below the protection level at the close of any business day and stays below the initial level on the final valuation date.

This product is a reverse

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

If you already have an account, please sign in here.

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: